← All opportunities

Horizon Europe · European Union

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

Open

The EU's Horizon Europe programme expects to make 4 awards of €8 million – €10 million each, from a total budget of €38 million. Applications close on 17 Feb 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.

Expected outcome

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication.

• Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities.

• Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines.

Scope

While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that around 5% of all hospital deaths are due to an adverse drug reaction. On average, 16% of hospitalised older [2] patients experience significant ADRs, varying in severity and mostly preventable, with commonly prescribed drug classes (such as diuretics, anti-bacterials, antithrombotic agents, analgesics, antineoplastics, etc.) accounting for most ADRs [3] . Overall, ADRs increase morbidity, mortality, hospitalisations, and healthcare costs.

ADRs from multiple medications contribute significantly to healthcare costs due to increased hospitalisations and treatments, making this an area of focus to achieve cost efficiency.

Initial failure to recognise ADRs can generate inappropriate prescription cascades, in which the side effects of drugs are misdiagnosed as symptoms of new problems, resulting in further prescriptions and further side effects that tend to accumulate, confusing and complicating the diagnostic while aggravating the evolution. Therefore, there is a distinct need for research to help identify and prevent such prescription cascades, possibly by maximising the use of technology, as well as to improve multiple drug management in order to reduce patient harm. Furthermore, it is also possible that aside from the ADRs specific to individual drugs taken in combination, new ADRs can emerge as results from the drug combinations themselves.

Who can apply

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Applicant categories are a starting point. The official call decides eligibility.

Topics

Biobanks Clinical Pharmacology Co-morbidity Health data Personalised services Personalised treatment Pharmacovigilance Tertiary prevention ADR adverse drug reactions co-morbidity multi-morbidity pharmacogenomics pharmacovigilance tertiary prevention

Timing

Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

How to apply

1. Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
2. Register each participating organisation in the Funding & Tenders Portal to get a PIC.
3. Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
4. Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
5. Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.

From the call text

Who can apply

Not stated in the call text we hold — check the official page

Company stage

Not stated in the call text we hold — check the official page

Single applicant or consortium

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where applicants must be based

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where to apply

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Read the EU application guide

Where these facts come from

Official sources

Official call page

Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.

More from Horizon Europe